COVID-19
Conditions
Interventions
Experimental group (specific COX-2 inhibitor Celecoxib):N/A
Control group (non-specific cyclooxygenase inhibitors):N/A
Sponsors
Chongqing University Three Gorges Hospital
Eligibility
Sex/Gender
All
Age
14 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. COVID-19 nucleic acid test positive cases, and meet the diagnostic criteria of the Diagnosis and Treatment Plan for novel coronavirus Pneumonia (Tenth Edition for Trial Implementation); 2. Age is more than 14 years old; 3. The COX-2 inhibitor celecoxib, or highly selective non steroidal drugs such as ibuprofen, or non steroidal drugs not used at home, in the outpatient department or after admission, were taken for more than 1 day.
Exclusion criteria
Exclusion criteria: 1. Non COVID-19 pneumonia confirmed cases; 2. COVID-19 patients who did not use non steroidal drugs for less than 1 day; 3. Patients younger than 14 years old; 4. Missing clinical data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IL-6;Symptom relief situation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Nucleic acid conversion time;Adverse event occurrence rate;All-cause mortality rate; | — |
Countries
China
Contacts
Public ContactWang Hailong
Chongqing University Three Gorges Hospital
Outcome results
None listed